Vision impairment is a major cause of disability. In Europe, an average of 1 in 30 people experience sight loss. Treatment of ocular diseases is a top priority today. However, the arsenal of medications remains rather restricted to traditional drugs despite improvements in pharmacological treatments. In this context, the EU-funded DYE-LIGHT project will explore new ways to deliver biotherapeutics and perform ocular surgery. Going beyond current methods that include eye drops and injections, the project will consider the use of pulsed lasers at much lower energy levels than currently used in ocular surgery in combination with nanoencapsulated vital dyes used by surgeons to stain tissues.